Precigen (NASDAQ:PGEN) Raised to “Strong-Buy” at Zacks Research

Precigen (NASDAQ:PGEN) was upgraded by Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other equities research analysts also recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. HC Wainwright lifted their target price on shares of Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday. Wall Street Zen downgraded Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a report on Thursday, May 14th. Finally, Citizens Jmp increased their price target on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Precigen presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Precigen Stock Performance

NASDAQ PGEN opened at $6.91 on Wednesday. Precigen has a 1 year low of $1.70 and a 1 year high of $7.23. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 4.12. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of -6.64 and a beta of 1.02. The company has a fifty day moving average price of $5.17 and a 200-day moving average price of $4.48.

Precigen (NASDAQ:PGEN) last announced its earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.06. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The company had revenue of $54.98 million during the quarter, compared to the consensus estimate of $27.98 million. The company’s quarterly revenue was up 6322.7% on a year-over-year basis. As a group, equities research analysts predict that Precigen will post -0.02 EPS for the current fiscal year.

Insider Transactions at Precigen

In other news, CEO Helen Sabzevari sold 346,836 shares of Precigen stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $5.89, for a total value of $2,042,864.04. Following the completion of the transaction, the chief executive officer owned 3,768,872 shares in the company, valued at $22,198,656.08. This trade represents a 8.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Rutul R. Shah sold 33,772 shares of Precigen stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $6.50, for a total transaction of $219,518.00. Following the completion of the transaction, the chief operating officer owned 497,751 shares of the company’s stock, valued at $3,235,381.50. The trade was a 6.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 956,500 shares of company stock valued at $5,248,371. 41.40% of the stock is currently owned by insiders.

Institutional Trading of Precigen

A number of institutional investors have recently modified their holdings of the business. Xponance LLC raised its position in shares of Precigen by 21.3% in the fourth quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,496 shares in the last quarter. BNP Paribas Financial Markets grew its position in Precigen by 6.1% during the third quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,993 shares in the last quarter. Composition Wealth LLC grew its position in Precigen by 16.5% during the fourth quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock worth $89,000 after buying an additional 3,000 shares in the last quarter. Intech Investment Management LLC grew its position in Precigen by 5.2% during the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock worth $263,000 after buying an additional 3,137 shares in the last quarter. Finally, Cetera Investment Advisers increased its stake in Precigen by 0.9% in the 1st quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock worth $1,449,000 after acquiring an additional 3,250 shares during the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Key Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 performance and profitability: Precigen reported that PAPZIMEOS revenue reached $53.1 million in the second quarter, roughly doubling sequentially. The company also achieved profitability, while earnings-call coverage highlighted a 145% increase in revenue. These results support the view that PAPZIMEOS is becoming a meaningful commercial product. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: Regulatory and commercial catalysts: FDA approval of PAPZIMEOS for recurrent respiratory papillomatosis, along with seven years of U.S. market exclusivity, strengthens the product’s revenue outlook. Potential European approval and expansion of Precigen’s AdenoVerse Immunotherapy platform—including PRGN-2009—could provide additional growth opportunities. Precigen Strong Buy and PAPZIMEOS Outlook
• Positive Sentiment: Analyst estimates moved higher: HC Wainwright reiterated its Buy rating and $18 price target, raising its FY2027 EPS forecast to $0.44 from $0.34. Estimates for Q4 2026 and each quarter of 2027 were also increased, while the FY2030 forecast rose to $1.49 from $1.44. These revisions signal greater confidence in the company’s earnings trajectory. HC Wainwright Reiterates Buy Rating for Precigen
• Neutral Sentiment: Unusually large options activity attracted attention, but the available report does not identify whether the transactions were bullish or bearish. Precigen Unusually Large Options Trading
• Negative Sentiment: One forecast was trimmed: HC Wainwright reduced its FY2028 EPS estimate slightly to $0.71 from $0.72, a minor offset to the broader upward revisions.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.